Distinct DNA damage determines differential phosphorylation of Chk2

Cancer Biology and Therapy

Volumn 15, Issue 12, 2014, Pages 1700-1704

  Ouchi, Mutsuko ^a   Ouchi, Toru ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ATM; Chk2; Dna damage; NBS1; P53; Phosphorylation

Indexed keywords

CHECKPOINT KINASE 2; DOXORUBICIN; REAGENT; ZINOSTATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; ENZYME KINETICS; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; HCT116 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; MUTANT; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHECKPOINT KINASE 2; DNA DAMAGE; DOXORUBICIN; HUMANS; PHOSPHORYLATION;

EID: 84920115087     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.972823     Document Type: Article

References (15)

1. Reinhardt HC, Yaffe MB. Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol 2013; 14:563-80; PMID:23969844; http://dx.doi.org/10.1038/nrm3640
2. Smith J, Tho LM, Xu N, Gillespie DA. The ATMChk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112; PMID:21034966; http://dx.doi.org/10.1016/B978-0-12-380888-2.00003-0
3. Buscemi G, Carlessi L, Zannini L, Lisanti S, Fontanella E, Canevari S,DeliaD.DNAdamage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol Cell Biol 2006; 26:7832-45; PMID:16940182
4. Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mittnacht S, Pearl LH. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 2006; 25:3179-90; PMID:16794575
5. Olsen BB, Larsen MR, Boldyreff B, Niefind K, Issinger OG. Exploring the intramolecular phosphorylation sites in human Chk2. Mutat Res 2008; 646:50-9; PMID:18812180; http://dx.doi.org/10.1016/j. mrfmmm.2008.09.002
6. Gabant G1, Lorphelin A, Nozerand N, Marchetti C, Bellanger L, Dedieu A, Qu-em-eneur E, Alpha-Bazin B. Autophosphorylated residues involved in the regulation of human chk2 in vitro. J Mol Biol 2008; 380:489-503; PMID:18538787; http://dx.doi.org/10.1016/j. jmb.2008.04.053
7. Dimitrova N, de Lange T. Cell cycle-dependent role of MRN at dysfunctional telomeres: ATM signaling-dependent induction of nonhomologous end joining (NHEJ) in G1 and resection-mediated inhibition of NHEJ in G2. Mol Cell Biol 2009; 29:5552-63; PMID:19667071; http://dx.doi.org/10.1128/MCB.00476-09. Epub 2009 Aug 10
8. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007; 26:7741-8; PMID:18066086
9. Ahn J,Urist M, Prives C. The Chk2 protein kinase.DNA Repair (Amst) 2004; 3:1039-47; PMID:15279791
10. Sancar A, Lindsey-Boltz LA, Unsal-Kącmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73:39-85; PMID:15189136
11. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006; 25:5912-9; PMID:16998506
12. Smith J, Tho LM, Xu N, Gillespie DA. The ATMChk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112; PMID:21034966; http://dx.doi.org/10.1016/B978-0-12-380888-2.00003-0
13. Jallepalli PV1, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003; 278:20475-9; PMID:12654917
14. Ahn J, Urist M, Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 2003; 278:20480-9; PMID:12654916
15. Grignani F1, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, Pelicci PG. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998; 58:14-9; PMID:9426049